The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers

Area of Science:

• Genomics
• Molecular Biology
• Cancer Research

Background:

• Adenosine-to-inosine (A-to-I) RNA editing is a prevalent post-transcriptional modification.
• The comprehensive genomic landscape and clinical significance of A-to-I RNA editing in cancer remain largely unexplored.

Purpose of the Study:

• To systematically investigate the global A-to-I RNA editing profiles across diverse cancer types.
• To identify clinically relevant RNA editing events and assess their functional impact on cancer biology and drug response.

Main Methods:

• Analysis of A-to-I RNA editing profiles in 6,236 patient samples from 17 cancer types using The Cancer Genome Atlas (TCGA) data.
• Experimental validation of the functional effects of specific RNA editing events on cell viability.
• Assessment of the influence of RNA editing on drug sensitivity.

Main Results:

• Significant diversity in altered RNA editing patterns was observed between tumor and normal tissues across various cancers.
• Numerous clinically relevant RNA editing events were identified, including many in noncoding regions.
• Experimental evidence demonstrated that specific nonsynonymous RNA editing events affect cell viability and can selectively alter drug sensitivity.

Conclusions:

• A-to-I RNA editing represents a crucial layer of post-transcriptional regulation with significant implications in cancer.
• Altered RNA editing patterns in tumors offer potential avenues for novel cancer biomarkers and therapeutic strategies.
• RNA editing warrants further investigation for its role in cancer mechanisms, diagnostics, and treatment.